Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADAR trial in early-stage Hodgkin lymphoma
NL-OMON59970Phase 3Recruiting
- Sponsor
- University College London
- Start
- Jun 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of brentuximab vedotin, doxorubicin, bleomycin, vinblastine and dacarbazine in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by University College London. Primary endpoint: Progression-Free Survival. Started Jun 2024; status: recruiting.
02
Drugs
brentuximab vedotindoxorubicinbleomycinvinblastinedacarbazine
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NL-OMON59970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59970.